The Great Biomarker Boom: Are We Overdiagnosing Risk or Finally Personalizing Medicine?

The Great Biomarker Boom: Are We Overdiagnosing Risk or Finally Personalizing Medicine? Review Abstract The rapid expansion of biomarker discovery and clinical application has created both unprecedented opportunities and substantial challenges in modern medicine. This analysis examines whether the current biomarker boom represents genuine progress

Ageotypes and Modern Longevity Biomarkers: What Physicians Should Monitor Beyond Telomeres

Ageotypes and Modern Longevity Biomarkers: What Physicians Should Monitor Beyond Telomeres Key Takeaways Stanford's ageotypes framework revolutionizes aging assessment by identifying four distinct aging patterns—metabolic, immune, hepatic, and nephrotic—enabling personalized longevity interventions beyond traditional approaches. • Telomeres alone are insufficient: Individual variation and tissue-specific differences

The Great Biomarker Boom: Are We Overdiagnosing Risk or Finally Personalizing Medicine?